Less than a year after AstraZeneca's lung cancer drug Tagrisso (osimertinib) was granted expanded reimbursement coverage, another round of discussions on its further expansion has begun, drawing attention to its background.

As the expansion request came from the medical community, not pharmaceutical companies, it will be interesting to see if the experts' request will be granted.

#On the 18th, according to the pharmaceutical industry and medical community, the Health Insurance Review and Assessment Service recently held the 8th Cancer Disease Deliberation Committee meeting in 2024 to deliberate on whether to set a reimbursement standard for Tagrisso.

The committee discuss